James E. Udelson

Q: What Schools Are Affiliated With James E. Udelson

James E. Udelson is affiliated with the following schools: Brown University, Yale University, Tufts University, University of Colorado, University of Massachusetts Medical School, Columbia University

James E. Udelson's AcademicInfluence.com Rankings

James E. Udelson

Medical

#2087

World Rank

#2485

Historical Rank

Cardiology

#181

World Rank

#186

Historical Rank

medical Degrees

James E. Udelson

Philosophy

#6154

World Rank

#9144

Historical Rank

Logic

#3343

World Rank

#4487

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

James E. Udelson's Degrees

Doctorate Medicine Stanford University

Why Is James E. Udelson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

James E. Udelson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007) (1532)
Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. (2002) (1287)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (1257)
ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionucl (2003) (1224)
Outcomes of anatomical versus functional testing for coronary artery disease. (2015) (1126)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci (2011) (1054)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (904)
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (889)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007) (818)
Coronary CT angiography versus standard evaluation in acute chest pain. (2012) (788)
ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionucl (2003) (769)
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. (2003) (749)
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy (2014) (698)
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial (2002) (672)
Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction (2006) (648)
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. (2008) (646)
Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. (2011) (598)
Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy (2006) (593)
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure (1996) (555)
Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina: A Phase I/IIa Double-Blind, Randomized Controlled Trial (2007) (554)
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. (1992) (545)
Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. (2000) (488)
Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. (2009) (435)
Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. (1994) (433)
Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. (1997) (424)
Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure (1992) (408)
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. (2009) (404)
Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. (1992) (402)
Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy (2008) (390)
Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. (2016) (389)
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. (2013) (388)
High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. (2014) (369)
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. (2010) (367)
An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis) (1998) (356)
Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. (2002) (346)
Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy (2010) (331)
Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure (2001) (331)
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. (1993) (304)
Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) (2017) (292)
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. (2005) (291)
Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy (2008) (285)
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. (2013) (285)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat (2015) (281)
Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. (2001) (265)
The case for myocardial ischemia in hypertrophic cardiomyopathy. (2009) (262)
Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial (2018) (260)
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2008) (259)
Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. (1998) (255)
Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. (2005) (254)
Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. (2015) (242)
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (233)
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. (2000) (231)
Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. (1998) (223)
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. (2012) (214)
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (197)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat (2015) (194)
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. (2001) (194)
Cardiac sympathetic imaging with mIBG in heart failure. (2010) (191)
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). (2005) (187)
Myocardial Metabolic, Hemodynamic, and Electrocardiographic Significance of Reversible Thallium‐201 Abnormalities in Hypertrophic Cardiomyopathy (1991) (181)
Metabolic Imaging With &bgr;-Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid Identifies Ischemic Memory After Demand Ischemia (2005) (179)
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. (2008) (178)
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. (2008) (178)
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. (1996) (172)
Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age (2013) (167)
Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. (2013) (166)
Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease (2000) (166)
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. (2008) (165)
Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. (2003) (164)
Randomized, Controlled Evaluation of Short- and Long-Term Benefits of Heart Failure Disease Management Within a Diverse Provider Network: The SPAN-CHF Trial (2004) (160)
Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment–Elevation Myocardial Infarction: A Pilot Study Using the Impella CP (2019) (158)
Minimum left ventricular pressure during beta-adrenergic stimulation in human subjects. Evidence for elastic recoil and diastolic "suction" in the normal heart. (1990) (155)
Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial (2007) (154)
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. (2007) (153)
2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. (2013) (152)
Right ventricular involvement in hypertrophic cardiomyopathy. (2007) (150)
Executive summary—can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? (2003) (149)
Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2010) (146)
Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. (1989) (145)
Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. (2006) (144)
Meta-analysis of exercise testing to detect coronary artery disease in women. (1999) (142)
Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy (2011) (140)
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. (2013) (138)
Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2008) (133)
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. (2011) (127)
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction (2010) (124)
PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial. (2014) (120)
Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term Progression of Left Ventricular Dilatation in Patients With Asymptomatic Systolic Dysfunction (1993) (117)
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide (2017) (115)
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. (2017) (115)
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial (2012) (109)
Ventricular remodeling in heart failure: a credible surrogate endpoint. (2003) (108)
Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy (2010) (104)
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia (2008) (102)
Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. (2000) (101)
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment (2020) (100)
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. (2013) (100)
An assessment of the positive predictive value and cost-effectiveness of dipyridamole myocardial scintigraphy in patients undergoing vascular surgery. (1994) (98)
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. (2001) (97)
Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. (2018) (94)
Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. (2012) (93)
Left Ventricular Diastolic Collapse: An Echocardiographic Sign of Regional Cardiac Tamponade (1991) (92)
Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. (2002) (91)
Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock (2020) (90)
34th Bethesda Conference: Can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? (2003) (90)
Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. (2018) (87)
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. (2011) (84)
2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology (2016) (84)
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. (2009) (83)
Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure (2007) (79)
Randomized, Controlled Dose-Ranging Study of the Selective Adenosine A2A Receptor Agonist Binodenoson for Pharmacological Stress as an Adjunct to Myocardial Perfusion Imaging (2004) (77)
Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging. (2009) (74)
The Future of Heart Failure Diagnosis, Therapy, and Management. (2016) (73)
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial (2018) (70)
Sex Differences in Functional and CT Angiography Testing in Patients With Suspected Coronary Artery Disease. (2016) (69)
34th Bethesda Conference: Executive summary--can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? (2003) (69)
Acute Hemodynamic Effects of Conivaptan , a Dual V 1 A and V 2 Vasopressin Receptor Antagonist , in Patients With Advanced Heart Failure (2001) (69)
Hyponatremia in patients with heart failure. (2005) (68)
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. (2009) (68)
Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial (2017) (68)
ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3) (2015) (66)
Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. (2015) (64)
Impact of Surgical Relief of Outflow Obstruction on Thallium Perfusion Abnormalities in Hypertrophic Cardiomyopathy (1992) (64)
Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia. Comparison to rapid atrial pacing. (1989) (64)
American society of nuclear cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center (2002) (64)
Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. (2001) (64)
Epicardial and paracardial adipose tissue volume and attenuation - Association with high-risk coronary plaque on computed tomographic angiography in the ROMICAT II trial. (2016) (63)
Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction (2016) (63)
New concepts in post-infarction ventricular remodeling. (2003) (63)
A New Noninvasive Method for the Estimation of Peak dP/dt (1993) (63)
Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial. (2010) (62)
Intermediate-Signal-Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy (2012) (61)
Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy: Under-Recognized Subset of Candidates for Heart Transplant (2014) (61)
Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. (2017) (60)
Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. (2014) (59)
American society of nuclear cardiology position statement on electrocardiographic gating of myocardial perfusion SPECT scintigrams (1999) (59)
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. (2020) (59)
Etiology and pathophysiology of new-onset heart failure: Evaluation by myocardial perfusion imaging (2009) (59)
Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation. (2001) (56)
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. (2009) (54)
Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. (2002) (53)
Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology. (2015) (52)
Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. (2000) (51)
Ventricular remodeling and its prevention in the treatment of heart failure. (1998) (50)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology. (2015) (50)
Heart failure with preserved ejection fraction. (2011) (50)
Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials (2017) (50)
Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. (2012) (49)
Steps forward in the assessment of myocardial viability in left ventricular dysfunction. (1998) (48)
Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. (1993) (46)
Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction (2016) (45)
Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease. (2020) (45)
hs-Troponin I Followed by CT Angiography Improves Acute Coronary Syndrome Risk Stratification Accuracy and Work-Up in Acute Chest Pain Patients: Results From ROMICAT II Trial. (2015) (45)
Sex Differences in the Effectiveness of Early Coronary Computed Tomographic Angiography Compared With Standard Emergency Department Evaluation for Acute Chest Pain: The Rule-Out Myocardial Infarction With Computer-Assisted Tomography (ROMICAT)-II Trial (2013) (45)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (45)
Drug and Device Effects on Peak Oxygen Consumption, 6-Minute Walk Distance, and Natriuretic Peptides as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction (2011) (44)
Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. (2009) (43)
Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease (2006) (41)
Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. (2018) (41)
Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. (2009) (41)
Comparison between the end-diastolic images and the summed images of gated 99mTc-sestamibi SPECT perfusion study in detection of coronary artery disease in women (1999) (41)
Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. (2012) (41)
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. (2015) (40)
Ventricular remodeling in heart failure and the effect of β-blockade (2004) (40)
Use of Coronary Artery Calcium Scanning Beyond Coronary Computed Tomographic Angiography in the Emergency Department Evaluation for Acute Chest Pain: The ROMICAT II Trial (2015) (40)
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial). (2014) (38)
Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. (2009) (37)
Physiologic significance of chronic coronary aneurysms in patients with Kawasaki disease. (1994) (37)
Ventricular remodeling fundamental to the progression (and regression) of heart failure. (2011) (37)
Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. (2005) (37)
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. (2011) (37)
Economic impact of beta blockade in heart failure. (2001) (35)
The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. (2011) (35)
Acute resting myocardial perfusion imaging in patients with diabetes mellitus: results from the emergency room assessment of sestamibi for evaluation of chest pain (ERASE Chest Pain) trial (2004) (34)
Right Heart Failure (1994) (34)
Comparison of Two Doses and Dosing Regimens of Tolvaptan in Congestive Heart Failure (2005) (33)
Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. (2005) (32)
Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. The SOLVD Investigators. (1992) (32)
Effects of Elamipretide on Left Ventricular Function in Patients with Heart Failure with Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. (2020) (32)
2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology (2016) (31)
Diastolic dysfunction as a cause of heart failure. (1993) (31)
Heart Failure With Improved Ejection Fraction: Is it Possible to Escape One's Past? (2018) (31)
Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. (2019) (30)
Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure. (2020) (30)
Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. (1997) (30)
Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination (2002) (29)
Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. (2020) (29)
Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (&bgr;-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy (2017) (29)
Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical services. (2012) (29)
Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. (2002) (28)
Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. (2008) (27)
PROGNOSTIC UTILITY OF CONTRAST-ENHANCED CARDIOVASCULAR MAGNETIC RESONANCE IN HYPERTROPHIC CARDIOMYOPATHY: AN INTERNATIONAL MULTICENTER STUDY (2012) (27)
Early Resting Myocardial Computed Tomography Perfusion for the Detection of Acute Coronary Syndrome in Patients With Coronary Artery Disease (2015) (27)
Combined analysis of resting regional wall thickening and stress perfusion with electrocardiographic-gated technetium 99m-labeled sestamibi single-photon emission computed tomography: Prediction of stress defect reversibility (1997) (27)
Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. (2019) (27)
Coronary Computed Tomography Angiography for Early Triage of Patients With Acute Chest Pain (2009) (25)
Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. (2015) (24)
Intravascular and Intracardiac Ultrasound Imaging: Current Research and Future Directions (1990) (24)
Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. (2003) (24)
Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative. (2013) (24)
Gender-based differences in brachial artery flow-mediated vasodilation as an indicator of significant coronary artery disease. (2005) (24)
Trials of Imaging Use in the Emergency Department for Acute Chest Pain. (2017) (24)
Identification of patients with stable chest pain deriving minimal value from coronary computed tomography angiography: An external validation of the PROMISE minimal-risk tool (2018) (23)
Acute Hemodynamic Effects of Tolvaptan , a Vasopressin V 2 Receptor Blocker , in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International , Multicenter , Randomized , Placebo-Controlled Trial (2008) (22)
Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI2P2S. (2020) (22)
Non-invasive fractional flow reserve derived from coronary computed tomography angiography in patients with acute chest pain: Subgroup analysis of the ROMICAT II trial. (2019) (22)
2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: an executive summary: a joint report of the ACR Appropriateness Criteria ® Committee and the ACCF Appropriate Use Criteria Task Force. (2013) (21)
Return to Play for Athletes After COVID-19 Infection: The Fog Begins to Clear. (2021) (21)
Predictive Model for High-Risk Coronary Artery Disease: Insights From the PROMISE Trial (2019) (21)
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials (2015) (21)
Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain (2020) (21)
Differences in the association of total versus local coronary artery calcium with acute coronary syndrome and culprit lesions in patients with acute chest pain: The coronary calcium paradox. (2018) (21)
Ventricular remodeling in heart failure and the effect of beta-blockade. (2004) (20)
Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose. (2017) (20)
High-Sensitivity Cardiac Troponin I as a Gatekeeper for Coronary Computed Tomography Angiography and Stress Testing in Patients with Acute Chest Pain. (2017) (20)
The historical and conceptual evolution of radionuclide assessment of myocardial viability (2004) (20)
Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. (1995) (20)
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial (2016) (20)
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial (2013) (20)
Comparative effects of verapamil and nitroprusside on left ventricular function in patients with hypertension. (1989) (20)
Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure (2017) (19)
Impact of Coronary Calcification on Clinical Management in Patients With Acute Chest Pain (2017) (18)
Bulls‐Eye Display and Quantitation of Myocardial Perfusion Defects Using Three‐Dimensional Contrast Echocardiography (2001) (18)
Echocardiography in low pressure cardiac tamponade. (1989) (18)
Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction (2010) (18)
Recurrent angina due to a left internal mammary artery-to-pulmonary artery fistula. (1993) (18)
Effect of acute angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: Relation to right ventricular volume (1990) (17)
Resting sestamibi imaging for the prognosis of low-risk chest pain. (1999) (17)
The impact of clinical data on interpretation of thallium scintigrams (1994) (16)
Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. (2005) (16)
Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. (1996) (16)
Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients (2002) (16)
Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1‐year outcomes: A patient‐level analysis of randomized clinical trials (2017) (15)
Foundation/American Heart Association Task Force on Practice Guidelines Cardiomyopathy : A Report of the American College of Cardiology 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic (2011) (14)
COCATS 4 Task Force 6: Training in Nuclear Cardiology. (2015) (14)
Left ventricular diastolic function and calcium channel blockers in hypertrophic cardiomyopathy (1994) (14)
Prevention and reversal of left ventricular remodeling: summation. (2002) (14)
Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations (2017) (13)
Evaluation of a new ultrasound contrast agent (AI-700) using two-dimensional and three-dimensional imaging during acute ischemia. (2002) (13)
Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. (2006) (13)
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). (2020) (13)
IMPROVED ASSESSMENT OF CAD IN OBESE SUBJECTS WITH FLURPIRIDAZ F18 PET MYOCARDIAL PERFUSION IMAGING: A SUBSET ANALYSIS OF THE FLURPIRIDAZ F18 301 PHASE 3 STUDY (2016) (13)
Training cardiovascular fellows in cardiovascular magnetic resonance and vascular imaging; Current status following the core cardiovascular training symposium (COCATS-2) guidelines. (2004) (13)
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial (2007) (13)
Time Delay, Infarct Size and Microvascular Obstruction After Primary PCI for ST-Segment Elevation Myocardial Infarction. (2021) (12)
Long-term health outcomes and cost-effectiveness of coronary CT angiography in patients with suspicion for acute coronary syndrome. (2020) (12)
Cost implications of selective preoperative risk screening in the care of candidates for peripheral vascular operations. (1997) (12)
Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? (1999) (12)
Coronary CT Angiography Versus Standard Emergency Department Evaluation for Acute Chest Pain and Diabetic Patients: Is There Benefit With Early Coronary CT Angiography? (2016) (12)
Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. (2020) (12)
The inaugural issue of Circulation: Heart Failure. (2008) (11)
T.M.I. (Too much information)? (2011) (11)
Left Ventricular Shape: The Forgotten Stepchild of Remodeling Parameters. (2017) (10)
The role of clinical data in interpretation of perfusion images. (1994) (10)
Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes. (2021) (10)
Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes. (1990) (10)
Future directions of myocardial fatty acid imaging (2007) (10)
Return to Play for Athletes After Coronavirus Disease 2019 Infection-Making High-Stakes Recommendations as Data Evolve. (2020) (10)
Age- and sex-based resource utilisation and costs in patients with acute chest pain undergoing cardiac CT angiography: pooled evidence from ROMICAT II and ACRIN-PA trials (2018) (9)
Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia (2019) (9)
Abstract 13294: Evidence for Reduced Mortality in an Adult Cohort With Hypertrophic Cardiomyopathy (2013) (9)
Lessons from the development of new adenosine A2A receptor agonists. (2008) (9)
Abstract 2479: Accurate Detection of Coronary Artery Disease by Echocardiography using Perflubutane Polymer Microspheres, a Novel Contrast Agent: Comparison with Nuclear Perfusion Imaging in Two Phase Three Multicenter Clinical Trials (2007) (9)
COCATS 4 Task Force 6: Training in Nuclear Cardiology (2015) (9)
Lake tahoe invitation meeting 2002 (2003) (9)
Choosing a thallium-201 or technetium 99m sestamibi imaging protocol (1994) (8)
Percutaneous Balloon Valvuloplasty and Coronary Angioplasty: What Kind of Guidance Would be Useful During the Performance of These Procedures? (1990) (8)
Hyponatraemia and vasopressin in heart failure: markers or mediators? (2011) (8)
Factors influencing exercise performance in patients with left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. (1998) (8)
Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. (2003) (8)
Intramyocardial Transplantation of Autologous CD 34 Stem Cells for Intractable Angina (2007) (8)
DISCORDANCES BETWEEN PREDICTED AND ACTUAL RISK OF ADVERSE EVENTS IN OBESE PATIENTS WITH SUSPECTED CARDIAC ISCHEMIA: INSIGHTS FROM THE PROMISE TRIAL (PROSPECTIVE MULTICENTER IMAGING STUDY FOR EVALUATION OF CHEST PAIN) (2017) (8)
DISCORDANCES BETWEEN PREDICTED AND ACTUAL RISK OF ADVERSE EVENTS IN OBESE PATIENTS WITH SUSPECTED CARDIAC ISCHEMIA: INSIGHTS FROM THE PROMISE TRIAL (PROSPECTIVE MULTICENTER IMAGING STUDY FOR EVALUATION OF CHEST PAIN) (2017) (8)
Hypervolemic Hyponatremia in Heart Failure. (2019) (7)
A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. (2018) (7)
Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial. (2016) (7)
Eighth Nuclear Cardiology Invitational Conference Park City, Utah, 2006 (2007) (7)
What is the "goal" serum potassium level in acute myocardial infarction? (2012) (7)
The price for probability: Comparing the costs of diagnostic testing strategies (2007) (7)
Imaging Coronary Anatomy and Reducing Myocardial Infarction. (2018) (7)
Relation between therapy‐induced changes in natriuretic peptide levels and long‐term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction (2016) (7)
Neuronal Dysfunction and Medical Therapy in Heart Failure: Can an Imaging Biomarker Help to “Personalize” Therapy? (2015) (7)
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors. (2022) (7)
Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure. (2011) (7)
Evaluating and Reducing the Risk of Sudden Death in Hypertrophic Cardiomyopathy. (2019) (7)
Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure? (2018) (6)
Can technetium 99m-labeled sestamibi track myocardial viability? (1994) (6)
Cocaine‐Using Patients With a Normal or Nondiagnostic Electrocardiogram: Single‐Photon Emission Computed Tomography Myocardial Perfusion Imaging and Outcome (2012) (6)
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). (2018) (6)
Abstract 16910: Can Spironolactone Mitigate Myocardial Fibrosis and Alter Sudden Death Risk and Heart Failure Symptoms in Patients With Hypertrophic Cardiomyopathy?: A Prospective, Randomized Trial (2013) (6)
How Accurate Is Quantitative Gated SPECT (2000) (6)
Coronary Computed Tomography Angiography Compared With Single Photon Emission Computed Tomography Myocardial Perfusion Imaging as a Guide to Optimal Medical Therapy in Patients Presenting With Stable Angina: The RESCUE Trial (2020) (5)
787 Prognostic value and changes in renal function in patients admitted with acute heart failure - results from the EVEREST program (2008) (5)
Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. (2009) (5)
Emergency department perfusion imaging for suspected coronary artery disease: the ERASE Chest Pain Trial. (2001) (5)
Testing our tests: surrogate end points versus driving patient management and outcomes. (2001) (5)
Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction (2020) (5)
EFFECTS OF A NOVEL TETRAPEPTIDE IN HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PHASE I RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ELAMIPRETIDE (2016) (5)
Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging (2021) (5)
Preload reserve a determinant of clinical status in patients with left ventricular systolic dysfunction (1991) (5)
Radionuclide imaging in risk assessment after acute coronary syndromes (2004) (5)
Effect of warfarin anticoagulation on survival in patients with left ventricular systolic dysfunction (1996) (5)
Advances in myocardial perfusion imaging (2012) (4)
Imaging techniques for the assessment of suspected acute coronary syndromes in the emergency department. (2014) (4)
Proceedings of the 3rd annual Acute Cardiac Unloading and REcovery (A-CURE) symposium (2019) (4)
A Head‐to‐Head Comparison of Infusion and Bolus Doses of Adenosine for Stress Myocardial Contrast Echocardiography (2006) (4)
The United Kingdom’s National Institute for Health and Care Excellence guideline on chest pain of recent onset: A United States perspective (2017) (4)
The Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization: Rationale and Design of the PRECISE Trial (2021) (4)
Quantitative instruments for predicting risk ... and benefit. (2005) (4)
Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. (2009) (4)
Is heart failure with preserved ejection fraction a ‘dementia’ of the heart? (2021) (4)
Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain. (2016) (4)
Compliance with Once Daily Controlled Release vs Twice Daily Immediate Release Carvedilol in Patients with Heart Failure: The CASPER Trial (2007) (4)
Effects of obesity on noninvasive test results in patients with suspected cardiac ischemia: Insights from the PROMISE trial. (2019) (4)
Effect of amiodipine on exercise tolerance and quality of life in mild-to-moderate heart failure with systolic dysfunction (1996) (4)
Assessment and key targets for therapy in the post-myocardial infarction patient with left ventricular dysfunction. (2008) (4)
Errors in Programming and Coding Affecting Cohorts Included in the Study Deriving and Validating the PROMISE Minimal-Risk Tool. (2018) (3)
Estimating the Real-World Performance of the PROMISE Minimal-Risk Tool: Nanna et al.: PROMISE Risk Score. (2021) (3)
Advancing the research mission of ASNC (2011) (3)
Abstract 18053: Prognostic Value of Anatomic versus Functional Diagnostic Testing in Symptomatic Patients With Suspected CAD: The PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) (2015) (3)
An example of medical device-based projection of clinical trial enrollment: Use of electrocardiographic data to identify candidates for a trial in acute coronary syndromes (2018) (3)
The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. (2015) (3)
Effects of the Vasopressin V2 Receptor Antagonist, Tolvaptan, on the Long-term Progression of Left Ventricular Dilatation in Patients with Heart Failure (2005) (3)
Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic Review (2020) (3)
15.27: Double-blinded comparison of the side effects associated with pharmacologic stress induced with binodenoson and adenosine (2008) (3)
The Heart Failure Society of America in 2020: a vision for the future. (2012) (3)
The correlation between myocardial perfusion and function regionally assessed by quantitative gated sestamibi tomography in acute myocardial infarction (1998) (3)
The PROMISE Minimal Risk Score Improves Risk Classification of Symptomatic Patients With Suspected CAD. (2022) (3)
IMPACT OF BASELINE VOLUME STATUS AND LVEF ON ALL-CAUSE MORTALITY IN THE BEST TRIAL (2010) (3)
Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. (2021) (3)
Abstract of the 15th annual inter ASC-ASCTS meetingPrognostic impact of myocardial viability testing in 3088 patients: A meta-analysis (2000) (3)
Abstract 18022: Improved Assessment of CAD in Women With Flurpiridaz F-18 PET Myocardial Perfusion Imaging: Results of Subset Analysis of the Flurpiridaz F-18 Phase 3 Study (2015) (3)
Trials and Tribulations of Assessing New Imaging Protocols: Combining Vasodilator Stress With Exercise. (2018) (3)
Rates of In-hospital Decongestion and Association with Mortality and Cardiovascular Outcomes among Patients admitted for Acute Heart Failure. (2022) (3)
Developing imaging biomarkers for myocardial involvement in amyloidosis: challenge and opportunity. (2015) (2)
Sex Differences in Functional Stress Test Versus CT Angiography in Symptomatic Patients With Suspected CAD : Insights From PROMISE (2016) (2)
Acute Effect of the V2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized with Heart Failure: Results of the SECRET of CHF (2016) (2)
PERFORMANCE OF TWO SENSITIVE TROPONIN I ASSAYS FOR THE EVALUATION OF SUSPECTED ACS: RESULTS FROM THE MULTICENTER RULE OUT MYOCARDIAL INFARCTION USING COMPUTER ASSISTED TOMOGRAPHY (ROMICAT) II BIOMARKER SUB-STUDY (2013) (2)
Vagus Nerve Stimulation for Chronic Heart Failure: Differences in Therapy Delivery and Clinical Efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF (2019) (2)
Abstract 13387: Highly Sensitive Troponin I and Coronary Computed Tomography Angiography Assessment of Stenosis and High-risk Plaque Permit Rapid Classification of Acute Coronary Syndrome Risk in Chest Pain Patients: Results from the ROMICAT II Trial (2014) (2)
Cardiac Magnetic Resonance Imaging for Long-Term Prognosis in Heart Failure. (2018) (2)
Seventh Nuclear Cardiology Invitational Conference, Park City, Utah, 2004 (2005) (2)
Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. (2019) (2)
Abstract 13139: Prognostic Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy: An International Multicenter Study (2012) (2)
DOES FOCAL LATE GADOLINIUM ENHANCEMENT AT THE RIGHT VENTRICULAR INSERTION POINTS MATTER IN RISK STRATIFICATION FOR SUDDEN DEATH IN HYPERTROPHIC CARDIOMYOPATHY (2013) (2)
Imaging in Coronary Artery Disease Risk Stratification. (2021) (2)
LACK OF PHENOTYPIC DIFFERENCES BY CMRI IN THE TWO MOST COMMON SARCOMERE PROTEIN GENE MUTATIONS IN HYPERTROPHIC CARDIOMYOPATHY (2013) (2)
Improved detection of reversible ischaemia by Tc-99m sestamibi compared to Tc-99m tetrofosmin SPECT imaging in mild to moderate coronary artery disease (1999) (2)
Prognostic and therapeutic implications of myocardial viability in patients with heart failure (2004) (2)
99mTc-SESTAMIBI gated SPECT perfusion study in detection of coronary artery disease in women: Comparison between the end-diastolic images and the summed images (1997) (2)
Primary Left Ventricular Unloading with Delayed Reperfusion in Patients with Anterior ST-Elevation Myocardial Infarction: Rationale and Design of the STEMI-DTU Randomized Pivotal Trial. (2022) (2)
Phase 2 clinical comparison of flurpiridaz F 18 injection PET and SPECT myocardial perfusion imaging for diagnosis of coronary artery disease (2011) (2)
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. (2022) (2)
Comparison of Imaging Modalities in the Assessment of Myocardial Viability (2007) (2)
Role of β-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. The post-myocardial infarction guideline committee (2003) (2)
Screening the population for coronary artery disease: Is it like screening for cancer? (2005) (2)
Gated SPECT myocardial perfusion imaging for the prediction of incident heart failure an old dog learns a new trick. (2009) (2)
Sudden Death Following Hospitalization for Heart Failure with Reduced Ejection Fraction (From the EVEREST Trial) (2018) (1)
174 - On-Body Performance of the sc2Wear™ Infusor for Subcutaneous (SC) Administration of a Novel Formulation of Furosemide in Patients with Heart Failure (HF) (2017) (1)
Endothelial Function/Coronary Blood Flow/Coronary Artery Disease Syndromes (2005) (1)
Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance (2014) (1)
Left Ventricular Diastolic Dysfunction as a Cause of Congestive Heart Failure (2020) (1)
TCT-2 Worse Outcomes in Women Compared to Men After Primary PCI in STEMI Are Not Explained by Infarct Size: A Collaborative Patient-Level Pooled Analysis of 10 Randomized Trials. (2016) (1)
233 Evidence that post-contrast delayed enhancement identified by cardiovascular magnetic resonance is an arrhythmogenic substrate in hypertrophic cardiomyopathy (2008) (1)
Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. (2005) (1)
Of infarct zone viability on regional and global ventricular geometry after anterior myocardial infarction (1996) (1)
Physiologic Guidance for Percutaneous Coronary Intervention: State of the Evidence. (2022) (1)
meta-analysis patients with coronary artery disease and left ventricular dysfunction: a Myocardial viability testing and impact of revascularization on prognosis in (2010) (1)
Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy (2015) (1)
Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook. (2022) (1)
Clinical and Economic Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease (2020) (1)
Clinical Implications of the PR Interval in Patients Hospitalized for Worsening Heart Failure and Reduced Ejection Fraction: Analysis of The EVEREST Study (2014) (1)
Calcium channel blockers in heart failure: help or hindrance? (1996) (1)
Abstract 20769: Sudden Cardiac Death Risk After Hospitalization for Heart Failure: Insights From EVEREST (2017) (1)
Chauges in Ventricular Volume, Wall Thickness and Wall Stress During Progression of Left Ventricular Dysfuncthu (2016) (1)
Diagnosis and Risk Stratification in Acute Coronary Syndromes (2021) (1)
Update on pharmacological cardiac stress testing: efficacy, risk stratification and patient selection. (2014) (1)
Enhanced hepatic uptake of thallium-201 in patients with severe narrowing of the right coronary artery. (1995) (1)
Is Heart Failure Etiology Destiny?: Outcome and Therapeutic Implications. (2019) (1)
Highlights of the 2005 scientific sessions of the American Society of Nuclear Cardiology: Seattle, Washington, September 29-October 2, 2005. (2006) (1)
eft Ventricular Remodeling in Heart Failure (2010) (1)
MIBG imaging for selecting heart failure patients for defibrillator therapy: A first step (2003) (1)
Editorial Commentary: Can noninvasive imaging techniques improve care for patients at risk for sudden cardiac death? (2016) (1)
PREVALENCE, CLINICAL PROFILE, AND OUTCOME OF CARDIORENAL SYNDROME IN SYMPTOMATIC PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2019) (1)
Abstract 2004: Usefulness of Coronary CT Angiography in the Early Triage of Patients with Acute Chest Pain (2008) (1)
Imaging highlights from the European Society of Cardiology, American Society of Nuclear Cardiology, and Heart Failure Society of America. (2008) (1)
PLACEBO EFFECTS ON KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE SCORES IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW OF CONTEMPORARY RANDOMIZED CONTROLLED TRIALS (2022) (1)
Clinical Investigations Factors Influencing Exercise Performance in Patients With Left Ventricular Dysfunction (1998) (1)
PARADIGM CHANGE IN THE DEMOGRAPHICS OF MORTALITY IN HYPERTROPHIC CARDIOMYOPATHY (2015) (1)
Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary Hypertension (2021) (1)
Ninth annual Mario S. Verani memorial lecture : testing our tests: the evidence bar is rising. Regulatory considerations in the development of cardiac imaging agents. (2011) (1)
Response to Letter Regarding Article, “Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction” (2007) (1)
Current concepts in the treatment of patients with heart failure (1998) (1)
K. Lance Gould, MD (born October 28, 1938) (2019) (1)
The Changing Face of Heart Failure. (2018) (1)
Abstract 14979: Progressive Heart Failure is Uncommon in Patients With Nonobstructive Hypertrophic Cardiomyopathy (2013) (1)
Chronic Conditions in Advanced Cardiac Disease: A Cluster Analysis of Transcatheter Aortic Valve Replacement (TAVR)-Treated Patients (2020) (0)
Treatment of Hypertrophic Cardiomyopathy (2011) (0)
TCT-263 Relationship Between Therapeutic Effects on Infarct Size in Acute Myocardial Infarction and One-year Outcomes: Patient-Level Analysis of Randomized Clinical Trials (2015) (0)
Prologue: putting the horse before the cart. (2002) (0)
Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH 7 ( βMyosin βMyosin βMyosin Heavy Chain )Versus )Versus )Versus MYBPC 3 ( MyosinBinding MyosinBinding MyosinBinding Protein C )Related )Related )Related Hypertrophic Cardiomyopathy (2017) (0)
Book Review Jablonski's Dictionary of Syndromes and Eponymic Diseases Second edition. By Stanley Jablonski. 665 pp., illustrated. Malabar, Fla., Robert E. Krieger, 1991. $99.50. (1992) (0)
Editor's Note. (2017) (0)
Vasodilators in Acute Heart Failure: Who Needs Them and How Soon? (2016) (0)
Incorrect Conclusions of a Secondary Analysis. (2018) (0)
Exercise Predicts Adverse Outcomes Among Patients With Coronary Artery Disease (2013) (0)
Abstract 18783: Predictive Model for High-Risk Coronary Artery Disease: An Analysis From PROMISE (2016) (0)
Editorial T . M . I . ( Too Much Information ) ? (2011) (0)
Reply (2018) (0)
Management and outcome of acute chest pain: influence of age and the use of SPECT myocardial perfusion imaging (2002) (0)
Journal of Nuclear Cardiology Nuclear Cardiology News Update (2000) (0)
2048 The hypertrophic cardiomyopathy phenotype revisited with cardiovasculara magnetic resonance (2008) (0)
HIGH-RISK PLAQUE PREDICTS ACUTE CORONARY SYNDROME INDEPENDENTLY OF SIGNIFICANT CAD IN PATIENTS WITH ACUTE CHEST PAIN: RESULTS FROM ROMICAT II (2014) (0)
Regional Comparison of Baseline Therapy in Patients Hospitalized for Acute Heart Failure with Systolic Dysfunction (2007) (0)
Therapeutics Effects on 6-minute Walk Distance as a Predictor of Therapeutic Effects on Mortality in Heart Failure Randomized Trials (2010) (0)
Striking a balance between quality and cost in PCI (2017) (0)
Reply: Chronic Kidney Disease Contributing to Dyspnea in Patients With Heart Failure. (2017) (0)
P4667Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials (2017) (0)
962-63 Stress-only Tc99m-Sestamibi Myocardial Perfusion Imaging in Patients with a Low Probability of CAD: Short-term Follow-up of a Streamlined Perfusion Imaging Protocol (1995) (0)
Abstract 14941: Left Ventricular Apico-Basal Muscle Bundle Identified by Cardiovascular Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: Implications for Diagnosis and Management (2012) (0)
Ventricular suction measurements by pressure volume relations (1987) (0)
Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. (2003) (0)
Echocardiographic Sign of Regional Cardiac Tamponade (2005) (0)
Post-Discharge Adjudicated Outcomes in Patients with Implantable Cardioverter-Defibrillators in the EVEREST Trial (2008) (0)
IMPACT OF OBESITY ON THE PHENOTYPE AND CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY (2012) (0)
Abstract 4706: Perfusion Stress Echocardiography with Perflubutane Polymer Microspheres Provides Incremental Predictive Value for Coronary Artery Disease Over Clinical Risk Factors (2008) (0)
Straining for Surrogacy. (2022) (0)
Effect of transplant center experience on post-transplant mortality for patients supported with an implantable left ventricular assist device: an analysis of the united network for organ sharing (UNOS) thoracic registry (2004) (0)
Panel VI. Assessing myocardial viability in left ventricular dysfunction and heart failure (1999) (0)
A biological model of commotio cordis: sudden death from low energy cheat wall impact (1998) (0)
Trials and Tribulations of Assessing New Imaging Protocols (2018) (0)
CRT-100.04 Delaying Reperfusion Plus LV Unloading Reduces Infarct Size: A Per-Protocol-Analysis of the STEMI_DTU Pilot Study (2023) (0)
40: Changes In the Neurohormonal Profile of Patients Hospitalized for Acute Heart Failure Syndromes During the Early Post-Discharge Period According to Early, Late, or No Heart Failure Re-Hospitalization or Mortality Events: Analysis From the EVEREST Trials (2010) (0)
3100Diamond and Forrester-predicted vs. coronary CTA-observed prevalence of obstructive CAD in patients with stable chest pain: results from the PROMISE trial (2018) (0)
1.05: Development and Retrospective Validation of a Risk-Adjusted, Gender-Matched Normal Database for I-123 BMIPP SPECT (2007) (0)
Development of Therapeutics for Heart Failure: Expedited Commentary. (2016) (0)
Characterization of tissue heterogeneity by contrast-enhanced cardiovascular magnetic resonance imaging is a powerful predictor of ventricular tachyarrhythmias on ambulatory holter ECG in hypertrophic cardiomyopathy (2009) (0)
Forum for Early Career Clinical Investigation: New Section for Circulation: Heart Failure. (2015) (0)
Advances in Cardiac Imaging: Mind the (Translational) Gap. (2021) (0)
Interpreting cardiac imaging. (1993) (0)
Peripheral vascular endothelial function predicts exercise capacity in cardiac transplant recipients (2002) (0)
Comparison of Resting Scintigraphy With 201T1 and 99mTc-Sestamibi (2005) (0)
Is the 12-lead electrocardiogram of value in the prognostic assessment of patients with hypertrophic cardiomyopathy? (2010) (0)
FIRST Out-of-Hospital Administration of Intravenous Glucose-Insulin-Potassium in Patients With Suspected Acute Coronary Syndromes The IMMEDIATE Randomized Controlled Trial (2012) (0)
MY APPROACH to outpatients with suspected CAD. (2016) (0)
Focal LGE and Outcome in HCM JACC Cardiovascular Imaging 1 CLINICAL SIGNIFICANCE OF LATE GADOLINIUM ENHANCEMENT AT RIGHT VENTRICULAR ATTACHMENT TO VENTRICULAR SEPTUM IN HYPERTROPHIC CARDIOMYOPATHY Running title: Focal LGE and Outcome in HCM (2014) (0)
Abstract 10805: Does the 12-lead ECG Have Limitations in Detecting Hypertrophic Cardiomyopathy in the Pre-Participation Screening of Athletes? (2011) (0)
The Role of Vasopressin and Vasopressin Antagonists in Heart Failure (2007) (0)
Imaging the patient with a new diagnosis of heart failure in the contemporary era (2015) (0)
TESTING OUR TESTS: THE EVOLUTION OF EVIDENCE FOR CARDIAC IMAGING. (2020) (0)
Reversible Thallium-201 Abnormalities in Hypertrophic Cardiomyopathy (2005) (0)
Design and rationale for an international study of utilization and outcomes following pharmacologic stress spect imaging (2004) (0)
Agreement between four high-sensitivity cardiac troponin assays and non-invasive testing, clinical and quality of care outcomes based on the 2020 ESC guidelines: results from the ROMICAT II trial (2022) (0)
Abstracts of Original Contributions ASNC2017 The 22nd Annual Scientific Session of the American Society of Nuclear Cardiology (2017) (0)
248 Use of a Propensity Score to Examine Association between Rates of In-Hospital Decongestion and Mortality and Cardiovascular Outcomes Among Patients admitted for Acute Heart Failure (2022) (0)
Assessment of Regional Viability in the Infarct Zone Following Myocardial Infarction (2004) (0)
Use of a Propensity Score to Examine Association between Rates of In-Hospital Decongestion and Mortality and Cardiovascular Outcomes Among Patients admitted for Acute Heart Failure (2022) (0)
Assessment of Myocardial Perfusion and Left Ventricular Function in Acute Coronary Syndromes: Implications for Gated Myocardial Perfusion SPECT (2007) (0)
MAJOR ACHIEVEMENTS IN NUCLEAR CARDIOLOGY: V The historical and conceptual evolution of radionuclide assessment of myocardial viability (2004) (0)
Imaging Patients with Chest Pain in the Emergency Department (2015) (0)
Technetium-99m sestamibi-avid pulmonary sclerosing hemangioma discovered during myocardial perfusion imaging (1994) (0)
1056-142 Investigation of myocardial-gated SPECT imaging as an initial strategy in heart failure: The IMAGING in heart failure study (2004) (0)
Identification of ischemic myocardium with rest reinjection of thallium201 following dipyridamole stress-redistribution imaging (1991) (0)
15.1 Prognostic impact of myocardial viability testing in 3088 patients: a meta-analysis 1992–1999 (2001) (0)
Association of Therapeutic Effect on Functional and Physiological Markers and Change in Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction (2014) (0)
P ender-Related Differences n the Clinical Presentation and utcome of Hypertrophic Cardiomyopathy (2005) (0)
Does left ventricular assist device implantation volume affect post-cardiac transplant outcome? an analysis of the united network for organ sharing (UNOS) thoracic registry (2004) (0)
From the American Heart Association -Thalassemia Major: A Consensus Statement β Cardiovascular Function and Treatment in (2014) (0)
Endothelial Function Peripheral Vascular Endothelial Function Testing as a Noninvasive Indicator of Coronary Artery Disease (2016) (0)
Impact of Surgical Relief of Outflow Obstruction (2005) (0)
INCREMENTAL VALUE OF EARLY RESTING MYOCARDIAL CT PERFUSION ASSESSMENT TO CARDIAC CT ANGIOGRAPHY FOR PREDICTION OF ACUTE CORONARY SYNDROME IN THE EMERGENCY DEPARTMENT (2014) (0)
P3522Vagus nerve stimulation for chronic heart failure: differences in therapy delivery and clinical efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF (2019) (0)
Peripheral arterial tonometry during hyperemia is blunted in patients with coronary artery disease (2003) (0)
Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress (2000) (0)
Abstract 553: Iodofiltic Acid I 123 SPECT Provides Incremental Diagnostic Value over Initial Clinical Information in Emergency Department Patients with Suspected Acute Coronary Syndrome (2008) (0)
Tolerability of the scFurosemide Infusor in Patients with Heart Failure (2018) (0)
CULPRIT LESIONS OF ACUTE CORONARY SYNDROME ARE CHARACTERIZED BY THE PRESENCE OF STENOSIS AND HIGH-RISK PLAQUE, BUT NOT HIGHER SEGMENTAL CORONARY ARTERY CALCIUM SCORE: RESULTS FROM THE ROMICAT II TRIAL (2015) (0)
New onset heart failure: influence of gender on underlying pathophysiology (2004) (0)
Ventricular in heart failure and the effect of β-blockade (2004) (0)
Acute Declines in Kidney Function in the Context of Decongestion in Patients with Acute Decompensated Heart Failure (2022) (0)
Editorial Commentary: Coronary artery calcification on non-cardiac chest CT: Incidental but impactful. (2017) (0)
Angiogenesis Intracoronary Basic Fibroblast Growth Factor ( FGF-2 ) in Patients With Severe Ischemic Heart Disease : Results of a Phase I Open-Label Dose Escalation Study (2016) (0)
President's message: beyond perfusion imaging. (2000) (0)
TCT-34 Reduction of Infarct Size in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) With LAD Occlusion and LV Unloading Using a Micro-axial Pump for 30 Minutes Before PCI: Per-Protocol Analysis of the STEMI Door to Unload (DTU) Pilot Study (2022) (0)
Abstract 16182: Diabetics With Acute Chest Pain Have Similar Length of ED Stay From Early CCTA Compared to Standard Evaluation but More Downstream Testing and Radiation Exposure: The ROMICAT II Trial (2014) (0)
Clinical and Cost Implications of Deferred Testing in Low-risk Patients with Stable Chest Pain: A Simulation Using the PROMISE Trial. (2023) (0)
Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial. (2023) (0)
No-Implant Interatrial Shunt for HFpEF: Six-Month Outcomes From Multicenter Pilot Feasibility Studies. (2023) (0)
Editorial commentary: Two faces of Janus: The complexities of coronary artery calcium density and distribution. (2018) (0)
Abstract 3097: Significance of Delayed Enhancement with Contrast Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy (2007) (0)
Comparing prognostic value of imaging agents and imaging techniques. (2012) (0)
Cost-effectiveness Analysis Of Non-invasive Testing Strategies For Stable Chest Pain Evaluation - Comparison Of Functional Testing, Coronary CTA, And Non-invasive FFRCTBased On The PROMISE Trial (2020) (0)
Myocardial perfusion imaging in the emergency department may reduce unnecessary hospitalisations (2003) (0)
The ninth annual Mario S. Verani memorial lecture (2011) (0)
Ventricular Dysfunction Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left (2011) (0)
Effects of Oral Tolvaptan on Left Ventricular Dilatation and Function in Patients with Heart Failure and Left Ventricular Systolic Dysfunction (2005) (0)
Abstract 10369: Safety of Anatomic versus Functional Diagnostic Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) (2015) (0)
Populations presenting for a myocardial perfusion imaging study: Results from an international study of utilization and outcomes following pharmacologic stress spect imaging (2004) (0)
Journal of Nuclear Cardiology Nuclear Cardiology News Update (2000) (0)
Distribution of ischemia and fixed perfusion defects detected in an international, observational, study of pharmacologic stress spect myocardial perfusion imaging (2004) (0)
FEMALE GENDER IS ASSOCIATED WITH MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2012) (0)
Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy. (2018) (0)
The QRS Interval Predicts Mortality and Re-Hospitalization in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
Correlation of Ejection Fraction to Early Post-Discharge Sudden Death and All-Cause Mortality in The EVEREST Trial (2008) (0)
Glucose-Insulin-Potassium for Suspected Acute Myocardial Infarction—Reply (2012) (0)
Regional Differences in Baseline Characteristics and Outcomes in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
Drug and Device Effects on Short Term Markers as Predictors of Long Term Therapeutic Effect on Mortality and Hospitalization for Heart Failure in Patients With Heart Failure and Reduced Ejection Fraction (2012) (0)
TCT-706 Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? (2019) (0)
Design, rationale, and populations of an international outcomes and utilization study of pharmacologic stress SPECT myocardial perfusion imaging in contemporary practice (2008) (0)
Abstract 3015: Drug and Device Effects on Peak Oxygen Consumption as a Predictor of Therapeutic Effects on Mortality in Heart Failure Randomized Trials (2009) (0)
Randomized, Controlled Dose-Ranging Study of the Selective Adenosine A 2A Receptor Agonist Binodenoson for Pharmacological Stress as an Adjunct to Myocardial Perfusion Imaging Clinical Investigation and Reports (2004) (0)
Imaging in the Emergency Department or Chest Pain Unit (2006) (0)
TCT-828 Clinical Outcomes Following Focal Ablation – a New Technique for the Performance of Alcohol Septal Ablation (2018) (0)
Are observation periods necessary during initiation and uptitration of carvedilol in heart failure patients (1999) (0)
PCV127 EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE (2009) (0)
35 Regional differences in baseline characteristics and outcomes in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
Comparison of reinjection thallium201 and rest sestamibi for prediction of reversible regional left ventricular dysfunction (1997) (0)
3303Classification of patients with acute chest pain by analytical benchmarks and subsequent management recommendations - A comparison of three highly-sensitivity troponin assays in the ROMICAT trials (2019) (0)
1056-141 Is there value in follow-up stress testing for emergency department patients with chest pain and normal rest SPECT myocardial perfusion? (2004) (0)
Sex Differences in the Effectiveness of Early Coronary CT Angiography Compared to Standard Emergency Department Evaluation for Acute Chest Pain: The ROMICAT II Trial (2013) (0)
Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial (2020) (0)
Comparison of the Early (1995–1998) and Late (1999–2001) Experience with the use of Implantable Left Ventricular Assist Devices on Post-Transplant Mortality: An Analysis of the United Network for Organ Sharing (UNOS) Thoracic Registry (2004) (0)
TCT-163 Time to Reperfusion and Infarct Size in Patients With STEMI Undergoing Primary PCI: A Collaborative Patient-Level Pooled Analysis of 10 Randomized Trials. (2016) (0)
Original Article Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure (2011) (0)
Abstract 128: Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction (2016) (0)
EXCESS EPICARDIAL ADIPOSE TISSUE IS ASSOCIATED WITH HIGH-RISK CORONARY PLAQUE ON CCTA INDEPENDENT OF RISK FACTORS, CORONARY CALCIUM SCORE AND STENOSIS: RESULTS FROM THE ROMICAT II TRIAL (2015) (0)
Apical Aneurysm: An Important Consideration in Hypertrophic Cardiomyopathy Patients (2020) (0)
TCT-168 Worse Outcomes in Women Compared to Men After Primary PCI in STEMI Are Not Explained by Left Ventricular Morphology and Cardiac Function: A Collaborative Patient-Level Pooled Analysis from 9 Randomized Trials. (2016) (0)
1989:515-REPORTS ON HYPERTENSION Comparative Effects of Verapamil and Nitroprusside on Left Ventricular Function in Patients With Hypertension (2016) (0)
IDENTIFYING STABLE CHEST PAIN PATIENTS WITH SUSPECTED CORONARY DISEASE IN WHOM NONINVASIVE TESTING MAY BE SAFELY DEFERRED: INSIGHTS FROM THE PROMISE TRIAL (PROSPECTIVE MULTICENTER IMAGING STUDY FOR EVALUATION OF CHEST PAIN) (2016) (0)
3209High-risk coronary plaque is an independent predictor of major adverse cardiovascular events in patients with stable chest pain: Results from PROMISE (2017) (0)
CorrespondenceLetters to the editorReply (2005) (0)
Myocardial Sympathetic Innervation, Imaging (2013) (0)
Performance of Heart Failure Clinical Prediction Models: A Systematic External Validation Study (2021) (0)
PCV125 EVALUATION OF THE ASSOCIATION BETWEEN SERUM SODIUM AND LENGTH OF STAY (LOS) IN PATIENTS HOSPITALIZED FOR HEART FAILURE (2009) (0)
SIX MONTH RESULTS FROM FIRST IN HUMAN CLINICAL EXPERIENCE OF A NO-IMPLANT INTERATRIAL SHUNT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION (2022) (0)
2055 Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy (2008) (0)
Effect of a Single Subcutaneous Infusion of Furosemide Compared with Intravenous Bolus on Vital Signs in Patients with Heart Failure (2018) (0)
Short-Term Drug Effects on Hemodynamics as Predictors of Long-Term Therapeutic Effects on Mortality in Patients with Heart Failure and Left Ventricular Dysfunction (2013) (0)
Abstract 18647: Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With James E. Udelson?

James E. Udelson is affiliated with the following schools:

James E. Udelson's Academic­Influence.com Rankings

James E. Udelson's Degrees

Why Is James E. Udelson Influential?

James E. Udelson's Published Works

Published Works

What Schools Are Affiliated With James E. Udelson?

James E. Udelson's AcademicInfluence.com Rankings